Adipotide

01 · What it is

The primate study that made this compound famous reported kidney effects in every species tested, at the doses that worked.

The sentence is in the abstract of the 2011 Science Translational Medicine paper, and it is worth quoting exactly: “At experimentally determined optimal doses, monkeys from three different species displayed predictable and reversible changes in renal proximal tubule function” ¹.

Read the qualifiers as the authors wrote them. Optimal doses — not excessive ones. Three different species — not one susceptible strain. Predictable — dose-related, not idiosyncratic. Reversible — which is the reassuring word, and the only one. The paper’s MeSH indexing carries Kidney/pathology, Kidney/physiopathology and Kidney Function Tests ¹.

Fifteen years later, this guide located no human trial. A PubMed search on the compound name and its target designation returns nine records in total [1–7 and two unrelated], the most recent mentioning it dating from 2022 ⁷, and none from 2023 onward.

What it is. Adipotide is not a hormone, an incretin, or a receptor agonist. It is a ligand-directed peptidomimetic, sequence CKGGRAKDC-GG-(D)(KLAKLAK)₂, built in two parts: a homing sequence that binds a marker on the blood vessels supplying white fat, and a cytotoxic sequence that kills the cell it is delivered to. Treatment “induced targeted apoptosis within blood vessels of white adipose tissue” ¹.

It works by destroying tissue. Every other compound in this family changes signalling. This one kills the blood supply to fat. That is the mechanism, stated plainly by its designers, and it is why the kidney finding is not a side note — a cytotoxic payload directed by a homing peptide goes wherever the homing peptide goes.

02 · Evidence at a glance

Evidence grade

Preclinical — no human trial located

What it is

A ligand-directed peptidomimetic, CKGGRAKDC-GG-(D)(KLAKLAK)₂ ¹

Mechanism

Targeted apoptosis of blood vessels within white adipose tissue ¹

Primate renal finding

At optimal doses, monkeys of three species showed predictable and reversible changes in renal proximal tubule function ¹

Primate efficacy

Rapid weight loss and improved insulin resistance; MRI and DXA confirmed marked reduction in white adipose tissue ¹

Published challenge to the mechanism

A 2012 comment argues the weight loss may instead reflect a direct effect on food consumption ²

Rodent counter-evidence on that point

Glucose tolerance improved in a weight- and food-intake-independent manner, using pair-fed controls ³

Rodent metabolic detail

Serum insulin and triglycerides fell; pathways of mitochondrial dysfunction, oxidative phosphorylation and branched-chain amino acid degradation reversed ³

A formulation that outperformed it

A nanoparticle carrying the same targeting peptide reduced body weight at low dose, where the bioconjugate did not ⁴

The target

Prohibitin, also studied in ovarian cancer, luteinisation and TGF-β pathways ⁵

Total PubMed records for the compound and its target phrase

Nine

Most recent record mentioning it

2022 ⁷

Human trials

None located

Regulatory status

No marketing authorisation located

03 · Mechanism of action

A homing sequence bolted to a cell-killing sequence

The molecule has two functional halves. CKGGRAKDC binds prohibitin, a marker enriched on the endothelium of white adipose tissue vasculature; (D)(KLAKLAK)₂ is a pro-apoptotic sequence that disrupts mitochondrial membranes in the cell it reaches ^1,3. The design intent is that fat loses its blood supply and the surrounding tissue does not.

This is oncology thinking applied to adipose tissue, and the authorship reflects it — the work comes out of a cancer centre and the same group later published on an unrelated agent in the same journal ⁶. The strategy is real, well-established, and carries the risk profile of the strategy rather than of a hormone analogue.

Why the target matters beyond fat

Prohibitin is not exclusive to adipose vasculature. A 2017 paper examines a prohibitin-targeting peptide in the context of ovarian cancer, luteinisation and TGF-β pathways ⁵.

A homing sequence is only as selective as its target’s distribution. Prohibitin appearing in reproductive tissue biology is the kind of fact that determines whether “targeted” means confined. This guide located no biodistribution study resolving it.

The kidney, and what “targeted” did not cover

Renal proximal tubule cells are among the most avidly endocytic cells in the body, and are the standard site of injury for filtered peptides and small proteins. The primate study found changes in exactly that compartment, in three species, at optimal doses ¹.

Whether the renal effect reflects prohibitin expression in the kidney, ordinary proximal tubular handling of a filtered peptide, or something else, the located literature does not say. What it does say is that the effect was predictable and dose-related — meaning it was a property of the drug at working doses, not an accident.

A published dispute about whether the mechanism is the mechanism

A 2012 comment in the same journal argued that the weight loss reported in obese monkeys may instead reflect a direct effect of adipotide on food consumption, rather than apoptosis of adipose vasculature. The original authors replied ².

A drug that kills tissue and a drug that suppresses appetite have very different risk profiles, so this is not a technical quibble. The 2012 rodent study is the strongest available answer: it used pair-fed controls and found glucose tolerance improved in a weight- and food-intake-independent manner ³, which is hard to explain by reduced eating alone. That addresses the glucose endpoint. It does not fully settle the question for weight.

04 · Key research findings

Obese Old World monkeys, 2011. The ligand-directed peptidomimetic CKGGRAKDC-GG-(D)(KLAKLAK)₂ induced targeted apoptosis within blood vessels of white adipose tissue, producing rapid weight loss and improved insulin resistance. Magnetic resonance imaging and dual-energy X-ray absorptiometry confirmed a marked reduction in white adipose tissue. At experimentally determined optimal doses, monkeys from three different species displayed predictable and reversible changes in renal proximal tubule function. The authors position the compound as a prototype in a new class of candidate drugs that may be useful for treating obesity in humans, and open by noting that biological differences between rodents and primates are a major hurdle for translating anti-obesity strategies ¹.

Two things deserve credit and both are unusual. The study was done in primates specifically because the authors said rodent results do not translate — an argument against their own convenience. And the renal finding is in the abstract, not buried in supplementary tables. This is a well-conducted, honestly reported study, and what it honestly reports includes dose-limiting kidney effects.

Comment and reply, 2012. A published comment argued the weight effect may reflect a direct action on food consumption rather than vascular apoptosis; the authors replied ².

Obese mice on a high-fat diet, 2012. The pro-apoptotic peptide rapidly and potently improved glucose tolerance in a weight- and food-intake-independent manner, tested against both vehicle controls and mice pair-fed to the treated group. Serum insulin and triglycerides fell relative to vehicle; fatty acid and acylcarnitine profiles were distinct from both vehicle and pair-fed controls. Microarray analysis of adipose tissue found that pathways involved in mitochondrial dysfunction, oxidative phosphorylation and branched-chain amino acid degradation were altered by high-fat diet and reversed by the peptide. The authors conclude that the work suggests a novel role for adipose tissue vasculature in glucose homeostasis and lipid metabolism ³.

The pair-fed design is what makes this study worth its space. Comparing treated animals to animals fed the same reduced amount separates the drug’s effect from the effect of eating less — the exact confound raised in the comment ². This is the strongest methodological work in the guide, and its conclusion is a physiological insight rather than a therapeutic claim.

Nanoparticle comparison, 2013. Systemic injection of diet-induced obese mice with a low dose of a nanoparticle carrying the same targeting peptide reduced body weight — evidenced by a significant decrease in serum leptin — rather than the bioconjugate composed of the same targeting peptide and the cytotoxic sequence, which is adipotide ⁴.

The plain reading is that at low dose the nanoparticle formulation worked and the bioconjugate did not. If the therapeutic index is the problem — and a renal finding at optimal doses suggests it is — then a formulation change that lowers the effective dose is the logical response. That the field moved toward carrier systems ^4,7 rather than toward human trials of the bioconjugate is informative.

Prohibitin-targeting peptide in reproductive biology, 2017. The peptide examined in relation to ovarian cancer, luteinisation and TGF-β pathways ⁵.

Later nanoparticle work, 2022. Fatty liver and adipose tissue dual-targeting nanoparticles carrying a heme oxygenase-1 inducer, for obesity, obesity-induced type 2 diabetes and steatohepatitis ⁷.

The synthesis across this literature, and it is short enough to state in one sentence: one excellent primate study established both a striking effect and a dose-limiting organ finding, one rodent study defended the mechanism with a well-controlled design, the field then moved to nanoparticle formulations of the targeting concept, and the compound itself stopped generating publications.

05 · Evidence overview

06 · Safety profile

Animal data — and this is the section that matters most for this compound.

The primate study reports predictable and reversible changes in renal proximal tubule function at experimentally determined optimal doses, in monkeys of three different species ¹. The paper is indexed under Kidney/pathology, Kidney/physiopathology and Kidney Function Tests ¹.

Three features of that sentence should not be softened. The effect occurred at working doses, not above them. It occurred across three species, so it is not a quirk of one model. It was predictable, meaning dose-related and therefore a property of the compound.

The reassuring feature is reversible, on the observation period the study used. This guide has read the abstract and not the full paper, so it cannot state the duration of exposure, the magnitude of the change, the recovery period, or whether reversibility was assessed after repeated cycles.

Human data. None. No human trial was located.

What is genuinely unknown. Four things, and they compound.

The therapeutic index. A renal effect at optimal doses means benefit and organ effect occur in the same dose range. No study located here defines the separation between them.

What repeated dosing does. Reversibility after the exposure used in one study is not a statement about chronic or cyclical administration. No chronic or repeat-dose toxicology was located.

Where else the payload goes. The molecule delivers a cytotoxic sequence wherever its homing sequence binds, and prohibitin is not confined to adipose vasculature ⁵. No biodistribution study was located.

Everything about human exposure. There is no human safety data of any kind in the located literature — no phase 1, no case series, no pharmacovigilance report.

Stated in one sentence: this is a compound that works by killing tissue, whose only primate study found kidney effects at effective doses in every species tested, that has never been tested in a published human trial, and that has generated no new publications since 2022.

07 · US regulatory status

Current as of 7 September 2026. This guide located no marketing authorisation for adipotide in any jurisdiction, and no published human trial. Nothing in the located literature indicates that a clinical programme progressed.

This guide has not consulted FDA, EMA or any other regulatory record, and makes no statement about any agency’s determinations.

An unapproved drug cannot lawfully be supplied for human use in the United States outside an authorised clinical trial or a formal expanded-access pathway.

Under the World Anti-Doping Code, competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The renal finding is reported here from an abstract, not the full paper ¹. Magnitude, exposure duration, recovery interval and whether reversibility persists across repeated cycles are all unread. Retrieving the full text is the first verification item on this guide, and the finding is serious enough that the guide leads with it regardless.
2. No human trial was located, fifteen years after a primate study whose authors described the compound as a prototype that may be useful in humans ¹. Why no trial followed, this guide does not know.
3. The mechanism is disputed in the published record ². The rodent pair-fed study answers the challenge for the glucose endpoint ³; it does not fully settle it for weight.
4. The entire literature is nine records, of which seven are cited here. Two concern the compound directly in animals ^1,3, one is a comment ², one a formulation comparison ⁴, one a target-biology paper ⁵, and two are adjacent work ^6,7.
5. No biodistribution study was located, so the selectivity implied by “targeted” is not independently established in what this guide read.
6. No chronic or repeat-dose toxicology was located.
7. The nanoparticle comparison suggests the bioconjugate underperformed its own targeting peptide in another formulation at low dose ⁴. This guide reports that from a single study’s abstract.
8. Nothing has been published on this compound since 2022 ⁷. In a field where every other compound in this family generated dozens of 2026 records, silence is a datum.
9. No independent analysis of any product sold under this name was located. Given that the compound’s mechanism is cytotoxic, the absence of identity and purity data on marketed material is a more consequential gap here than for any other compound in this family.
10. This guide has read abstracts, not full texts, for every source cited.

09 · Legal and regulatory appendix

This appendix applies to every compound in this family and is reproduced in each guide.

Approval status. This guide located no marketing authorisation for adipotide and no published human trial. Supplying or administering an unapproved drug for human use is unlawful in the United States and in most other jurisdictions outside an authorised trial or expanded-access pathway. This guide does not describe how to obtain the compound and takes no position on any supplier.

Products sold under this name. Material sold as adipotide has no established relationship to the material used in the studies cited here. This guide located no published analysis of the identity, purity, concentration, sterility or contamination status of any such product.

Research-use labelling. Material labelled for laboratory research use is not manufactured, tested, or released to the standards applied to medicines intended for people, and such labelling does not make administration lawful or safe.

What this guide is. A description of the published peer-reviewed literature, written for readers who want to understand the state of the evidence. It is not medical advice, not a recommendation, not an endorsement, and not a substitute for a clinician who can assess an individual situation.

Editorial position. Arkham Labs publishes independently and earns through disclosed referral links. That commercial relationship is disclosed on every page carrying such a link and on the editorial standards page. It does not alter what the evidence says, and this guide leads with a dose-limiting kidney finding in three primate species because that is the most important thing the literature on this compound contains.

10 · References

1. Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011 Nov 9;3(108):108ra112.

   PMID 22072637 ↗

2. Criscione L. Comment on “A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys”. Sci Transl Med. 2012 Apr 25;4(131):131le2; author reply 131lr2.

   PMID 22539771 ↗

3. Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M, Newgard CB, Woods SC, Seeley RJ. Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium. Diabetes. 2012 Sep;61(9):2299–2310.

   PMID 22733798 ↗

4. Hossen N, Kajimoto K, Akita H, Hyodo M, Harashima H. A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. J Control Release. 2013 Oct 28;171(2):104–112.

   PMID 23871959 ↗

5. El-Etreby NM, Ghazy AA, Rashad R. Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-beta pathways. J Ovarian Res. 2017 Apr 20;10(1):28.

   PMID 28427435 ↗

6. Sharma G, Hu C, Staquicini DI, Brigman JL, Liu M, Mauvais-Jarvis F, Pasqualini R, Arap W, Arterburn JB, Hathaway HJ, Prossnitz ER. Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes. Sci Transl Med. 2020 Jan 29;12(528):eaau5956.

   PMID 31996464 ↗

7. Hong J, Kim YH. Fatty liver/adipose tissue dual-targeting nanoparticles with heme oxygenase-1 inducer for amelioration of obesity, obesity-induced type 2 diabetes, and steatohepatitis. Adv Sci (Weinh). 2022 Nov;9(33):e2203286.

   PMID 36209391 ↗